Method for preparation of polypeptide with properties of factor release of growth hormone

专利摘要:
Human pancreatic GRF and the hypothalamic GRFs for the human and several other mammalian species were earlier characterized and synthesized. The invention provides synthetic peptides which are potent stimulators of the release of pituitary GH in animals, including humans, and which have the formula: R1-R2-R3-Ala-R5-R6-R7-R8-R9-R10-R11-R12-R13-Leu-R15-GIn-Leu-R18-R19-R20-R21-Leu-Leu-Gln-Glu-R26-R27-R28-Arg-Y wherein R, is Tyr, D-Tyr, Met, Phe, D-Phe, Leu, His or D-His, which has either a CaMe or NaMe substitution or is unsubstituted; R2 is Ala or D-Ala; R, is Asp or D-Asp; R5 is lie or Leu; R6 is Phe or Tyr; R, is Ser or Thr; R5 is Ser, Asn, Thr or Gin; R, is Ala or Ser; R10 is Tyr, Phe or Leu; R11 in Arg, Om or Lys; R,, is Arg, Om or Lys; R13 is Ile, Leu, Phe or Val; R15 is Gly or Ala; R18 is Ala or Ser; R19 is Ser or Ala; R20 is Arg, Om or Lys; R21 is Arg, Om or Lys; R26 is Leu, Ile, Val or Phe; R27 is Nle, Nva or a natural amino acid; R28 is Ala, Leu, Asn, Gin, or Ser; and Y is OH or NH2; provided however that at least four of the residues constituting Rs, R5, R7, Ra, R9, R,o, R11, R12, R13, R15, R18, R19, R20, R21 and R26 are different from the residues appearing in that respective position in the native molecule. These peptides as well as non- toxic salts thereof may be administered to animals, including humans and cold-blooded animals, to stimulate the release of GH and may be used diagnostically.
公开号:SU1651787A3
申请号:SU864027997
申请日:1986-08-22
公开日:1991-05-23
发明作者:Томас Кайзер Эмиль；Велиселеби Гонал
申请人:Дзе Салк Институт Фор Биолоджикал Стадиз (Фирма)；
IPC主号:

专利说明:

This invention relates to biochemistry, in particular to the synthesis of peptides that affect the function of the pituitary gland in humans and animals, mainly peptides that stimulate the release of growth hormone by the pituitary gland.
The aim of the invention is to simplify the way
Such peptides can be synthesized by the solid phase method.
The method is that the labile side chain groups of different
Amino acid fragments are protected with suitable protecting groups that prevent the chemical reaction to take place in this area until the protecting group is not bugs. det completely removed. The traditional technique is to protect the alpha-amino group of an amino acid or fragment during the reaction of the system at the carboxyl group, after which the alpha-protecting group is selectively removed for
s
J1
maintaining subsequent reactions, accordingly, producing intermediates that include amino acid residues located in the desired sequence in the peptide chain, where protective groups of the side chain are attached to the corresponding residues, where BOC is tert-butyloxycarbonyl; MVPA - resin;
OB21 — an etheric protecting group for the carboxyl group, such as Asp or Glu; Bzl is a benzyl hydroxyl-protecting group for Serj; Hap is a protecting group for an amido group, such as xanethyl; TOS - protective group for imidazole nitrogen
Example 1 „Synthesis of Ser 7, 8, 19 Ala 9, 15, 18, 28, Arg 12, 21, Leu 13,26, 27 - hGRF (1-29) - NIi2, corresponding to the formula H-Tyr-Ala, Asp -Ala- Ile-Piie S er-S er-Ala-Tug-Arg-Arg-Leu-Leu-Ala-Glu-Leu-Ala-Ser- -Arg-Arg-Leu-Leu-Gln-Glu-Leu- Leu-
-Ala-Arg-NIL, carried out stepwise using Beckman 990 peptide synthesis on an MBHA resin. having a replacement interval of 0.35-0.5 mmol / g of resin Compound BOC-Aig (TOS) with a resin is carried out according to the general procedure described in U.S. Patent 4,292,313 (Vale), using CR in DMF medium at 60 ° C for 24 hours with stirring. As a result, a substitution of 0.35 mmol Arg per 1 g of resin is achieved.
After deblocking and neutralization, the peptide chain is sequentially arranged on the resin. The neutralization is released and each amino acid is added in accordance with the general procedure. All solvents used are thoroughly degassed by purging with an inert gas, such as helium or nitrogen, in order to ensure the absence of oxygen
Release is carried out in accordance with mode A, min:
60% TPA / 20% ethanedithiol
60% TFA / 2% ethanediol 15
1PA / 1% ethanediol 0.5
Et3N (10%) in CHgClfc0,5
MeOH0.5
Et3N (10%) in CHgClj, 0.5
Meon (twice) 0.5
CHZC12 (twice) 0.5
Combination operations are carried out in accordance with mode B, min:



, "

2Q 5
™
.
35
40
0
five
DSS1
BOC-amino acid 50-90
MeOH- (twice) 0.5
SNG1g (twice) 0.5
Ac20 (ЗМ) in СН2С1г15,0
.0,5
heOH0,5
CHgClg. (twice) 0.5
The operations described are as follows: 1-2 mmol of a BOC-protected amino acid in methylene chloride is used per g of resin, 1 eq, 1.0 M solution of DCC1 in methylene chloride is added within 2 hours. the combination is subjected to BOC-Arg (TOS), using a mixture of 50% DMF and methylene chloride. Benzyl ether is used as the protective group of the side-chain hydroxyl Ser and Thr. The amido group of Asn and Gin is protected with Hap when using a BCA combination, this is preferred.
The n-nitrophenyl ether (ONp) can be used to activate the carboxyl end of Asn or Gin and, for example, BOQ-Asn (ONp) can be conjugated overnight using 1 equiv. HOBt in a 50% mixture of DMF and methylene chloride, in which case BCA is not added. For the Lys side chain, 2-chloro-benzyloxycarbonyl (2C1-Z) 0 Tos is used as a protective group to protect the guanidine Arg and also the imidazole nitrogen His, and the carboxyl group of the side chain Glu or Asp is protected with OBZ1. The phenolic hydroxyl group Tug is protected by 2,6-dichlorobenzyl (DSB). By the end of the synthesis, the following composition is obtained: BOC-Tyr (x) -Ala-Asp (X2) -Ala-Ile-Phe-Ser- (X3) -Ser- (X3) -Ala- - Tu g (X) -Arg (X f) -Arg (Xr) -Leu-Leu- (X4) -Leu-Ala-Ser (X3) -Arg (X) -Arg (X) -Leu-Leu-Gln- (X4) -Glu ( Xe) - -Leu- Leu-Ala-Arg (X) -X, where X - DSW; Hg - OBZ1; X - Bzl, X - Xan; TOS; X - substrate - HN-resin
Xan is completely or partially removed by treatment with TFA used to unlock the a-amino protecting group.
51
To cleave and remove the protective group from the peptide-resin system, the latter are treated with 1.5 ml of anisole, 0.5 ml of methyl ethyl sulfide and 15 ml of hydrogen fluoride per g of peptide resin system for 0.5 h at -20 ° C and for 0.5 h at 0 ° C. After HF has been removed under high vacuum, the remaining peptide-resin system is alternately washed with dry diethyl ether and chloroform, and then the peptide is extracted with degassed 2X acetic acid and separated from the resin by filtration.
Then, the peptide cleaved and deprived of the protective group is dissolved in a 0-5% solution of acetic acid and purified, which may include a stage of filtration through a fine-grained Sephdtex C-50 gel
Then the peptide is subjected to additional purification by preparative or semi-preparative liquid chromatography at high pressure (HPIC). The composition of the chromatographic fractions is carefully controlled by HPIC and only those fractions that are of sufficient purity are discharged. Desalting of the purified fractions independently tested for frequency is achieved using a gradient in 0.1% TFA. Then the central section is lyophilized to form the desired peptide with a purity higher than 98%.
Example 2. Synthesis of a peptide having the same sequence of amino acid residues, but in the form of free acid, i.e. Ser 7,8,19, Ala 9,15,18,28, Arg 12,21, Leu 13, 26,27 - GPF (corresponding to the formula:
H-Tyr-Ala-Asp-Ala-Ile-Phe-Ser-Ser-Ala-Tyr-Arg-Arg-Leu-Leu-Ala-Gln- -Leu-Ala-Ser-Arg-Arg-Leu-Leu-Glu - -Glu-Leu-Leu-Ala-Arg-OH, was carried out in a stepwise manner using a Beckman 990 peptide synthesizer on a chloromethylated resin having a replacement interval of 0.35-0.5 mmol / g resin. BOC-Arg (TOS ) with the resin was carried out according to the general procedure, using methylene chloride as the solvent, for 2 hours with stirring, add 1 eq. 2M solution of DSS1 in methylene chloride. As a result, a degree of substitution is achieved.
87
about 0.35 mmol of Arg per g of resin; the remaining synthesis operations, including splitting, removing the protective group and cleaning, are carried out according to
example 1.
In accordance with the analysis performed by thin layer chromatography and HPIC, it was found that
obtained almost pure peptide of a new type.
X1 may be a suitable protecting group for the phenolic hydroxyl group of tyrosine.
(Tar), for example, such as tetrahydropranyl, tert-butyl, trityl, Bzl, CBz, -CBz and 2,6-dichlorobenzyl (DSB). The preferred protecting group is 2,6-dichlorobenzyl.
X may be hydrogen, which means the absence of a protective group in the side chain of the amino acid residue in this position. Xz is hydrogen or is -
an ether ester protecting group for the carboxyl group of aspargin (Asp) or glutamine (Glu), such as benzyl (OBzI), 2,6-dichlorobenzyl, methyl or ethyl
X may be a suitable protecting group for the hydroxyl group of threonine (Tlir) or seryl (Ser), for example Bzl, 2,6-dichlorobenzyl and CBz. Preferred
the protecting group is Bzl,
X may be hydrogen, which (implies the absence of a protecting group on the hydroxyl group. X is hydrogen
or a suitable protecting group for the amido group of the side chain of Ash or glycine (Gin). Preferably, such a group is xanthyl (Hap).
5 X is a suitable protecting group for the guanidine group of arginine (Arg), such as nitro-TOS, CBz, adamantyloxycarbonyl, and also BOC or hydrogen.
The selection of the group to protect the amino group of the side chain is not critical, except that usually such a group is chosen that is not removed during the operation.
on the deprotection of amino groups during the synthesis. However, for some amino acids, e.g., histidine (His), there is usually no need for protection after completion of the
in this case, the protecting groups may be the same.
X is a suitable protecting group for the C-terminal carboxyl group or is the root bond used in solid-phase synthesis for bonding to a solid resin substrate, or is des-X1, in that when the Arg residue is amidated at the C-terminus. When such a solid resin backing spoon is used, it is considered as a protective group and corresponding protecting groups of this type can be chosen from the following systems: O- CH-synthetic substrate, -Sh-bin hydrilamine (BHA) - synthetic substrate, or -NH-napa methylbenzhydrylamine (MBHA) - synthetic substrate In the case where the presence of an unsubstituted amide group is desirable, the BHA or MBA is desired, since cleavage directly leads to the formation of amide groups.
Solid phase synthesis begins at the C-terminal end of the peptide by conjugating the protected a-amino acid with a suitable resin. Such starting material can be obtained by adding an a-amino protected amino acid via an ester bond to a chloromethylated resin or hydroxymethyl resin, or by amide linking. - D to VNA resin or MVNA resin.
The C-Terminal amino acid protected by BOC and TOS may initially be conjugated with a chloromethylated resin or with a BHA or MBHA resin. After conjugation of a BOC-protected amino acid with a resin support, the a-amino protecting group is removed, for example, by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. Removal of the protective group is carried out at a temperature of from 0 ° C to room temperature.
Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in a about fourfold or higher excess and conjugation can be carried out in a medium that is a mixture of dimethylformamold (DMF) and (1: P or each of
d 15 20 25
30 $
40 45
50
five
These substances separately. In cases where incomplete conjugation takes place, the operation is repeated until the a-amino protecting group is removed before adding the next amino acid. The degree of reaction of the combination at each stage of the synthesis, if the reaction is carried out manually, is preferably recorded by the ninhydrin reaction. The reaction of the combination can be carried out automatically, for example, in the Beckmann automatic synthesizer 990.
After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the substrate from the resin as a result of treatment with a reagent such as liquid hydrogen fluoride, which not only cleaves the peptide from the resin, but also removes all remaining protective groups of the side chain X X2-, X e , X4, Xs, as well as an a-amine protecting group, to obtain an amidated peptide. The BOC protecting group is first removed using trifluoroacetic acid-ethachdithiol prior to cleaving the peptide from the resin with HF. When used to split hydrogen fluoride, anisole and methylethylsulfide are introduced into the reaction vessel as acceptors.

权利要求:
Claims (2)
[1]
Invention Formula
The method of obtaining a polypeptide with the properties of a growth hormone release factor, BKLKG cleansing the final product, characterized in that, in order to simplify the method, solid phase synthesis of the peptide formula is carried out
H-Tyr-Ala-Ala-Ile-Phe-Ser-Ser-Ala-Tür-Arg-Arg-Leu-Leu-Ala-Gin-Leu-Ala-Ser-Arg-Arg-Leur-Leu-Gin-Glu - -Leu-Leu-Ala-Arg-Y, where Y is OH or H-group, by combining BOC-protected amino acids with MBHA or a chloromethylated resin to form a peptide having one BOC protective group; -Tug (X) -Ala-Asp (X2) -Ala-Ile-Phe- -Seir (X3) -Ser (X) -Ala-Tyr (X) -Arg (Xr) - -Arg (X5) -Leu- Leu-Ala-Gln (X4) -Leu- -Ala-Ser (X5) -Arg (X5) -Arg (Xf) -Leu- -Leu-Gln (X4) -Glu (X) -Leu-Leu-Ala- -Arg (Xr) -X9,
9 1651787Y
where X, - 2,6-lichlorobenzyl, groups and peptide separation from the polymer
[2]
2. OBzl; media carrier using a mixture with
Xj - Bzl; holding 1.5 ml of anisole, 0.5 ml I
X 4 - ap of ethyl ethyl sulfide and 15 ml of fluoride
Xf SW; hydrogen per g system
X — bond to a polymeric carrier — peptide-resin for 0.5 h at
lem with the subsequent removal of protective

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1651787A3|1991-05-23|Method for preparation of polypeptide with properties of factor release of growth hormone

---

EP3398960B1|2020-05-13|Method for preparing semaglutide

---

JP4405594B2|2010-01-27|Improved solid phase peptide synthesis and reagents for use in such synthesis

---

ANDREU et al.1985|Solid‐phase synthesis of PYLa and isolation of its natural counterpart, PGLa [PYLa‐|] from skin secretion of Xenopus laevis

---

Nakagawa et al.1983|Synthesis of protected peptide segments and their assembly on a polymer-bound oxime: application to the synthesis of a peptide model for plasma apolipoprotein AI

---

RU2625793C2|2017-07-19|Method for therapeutic peptides synthesis

---

OA11501A|2004-05-14|Process for the preparation of resin-bound cyclic peptides.

---

Katsoyannis1964|The synthesis of the insulin chains and their combination to biologically active material

---

WO1993003056A1|1993-02-18|Lanthionine bridged peptides

---

TJOENG et al.1990|Multiple peptide synthesis using a single support |

---

KISO et al.1992|Efficient solid phase peptide synthesis: Use of methanesulfonic acid α‐amino deprotecting procedure and new coupling reagent, 2‐| oxy‐1, 3‐dimethylimidazolidinium hexafluorophosphate |

---

US4098777A|1978-07-04|Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn

---

KR100493795B1|2005-09-09|Synthesis of vip analog

---

US4965343A|1990-10-23|Method of peptide synthesis

---

JP2003519629A|2003-06-24|Use of non-peptide constrained mimetics of dipeptides or tripeptides in the synthesis of oligomers and artificial proteins and polypeptides

---

Lyle et al.1987|Chemical synthesis of rat atrial natriuretic factor by fragment assembly on a solid support

---

CA2069654C|2003-07-01|Peptide process

---

Lloyd-Williams et al.1991|Convergent solid-phase peptide synthesis. X. Synthesis and purification of protected peptide fragments using the photolabile Nbb-resin

---

JP2008534639A|2008-08-28|Peptide synthesis of alpha-helix on PEG resin

---

RU2276156C2|2006-05-10|Method for synthesis of tryptophane residue-containing peptide

---

Pallai et al.1983|Extended retro‐inverso analogs of somatostatin

---

US6448031B1|2002-09-10|Process for producing LH-RH derivatives

---

Lloyd-Williams et al.1993|Convergent solid-phase peptide synthesis. XI. Synthesis and purification of protected peptide segments spanning the entire sequence of the uteroglobin monomer using the photolabile nbb-resin.

---

TZOUGRAKI et al.1980|SYNTHESIS OF HUMAN β‐ENDORPHIN IN SOLUTION USING BENZYL‐TYPE SIDE CHAIN PROTECTIVE GROUPS

---

Brown et al.1983|Peptide synthesis. Part 5. Solid-phase synthesis of [15-leucine] little gastrin

同族专利:

---

公开号 | 公开日

---

AU6183886A|1987-03-05|

---

AU589674B2|1989-10-19|

---

KR910002701B1|1991-05-03|

---

IN163758B|1988-11-05|

---

AT69821T|1991-12-15|

---

EP0216517A2|1987-04-01|

---

EP0216517B1|1991-11-27|

---

KR870002163A|1987-03-30|

---

NO863432L|1987-03-02|

---

JPS6251698A|1987-03-06|

---

HUT41819A|1987-05-28|

---

PH23188A|1989-05-29|

---

NZ217280A|1989-04-26|

---

HU206126B|1992-08-28|

---

US4689318A|1987-08-25|

---

EP0216517A3|1988-09-21|

---

DE3682641D1|1992-01-09|

---

IL79534D0|1986-10-31|

---

ZA865886B|1987-03-25|

---

ES2001274A6|1988-05-01|

---

DK413986D0|1986-08-29|

---

JPH0762037B2|1995-07-05|

---

GR862194B|1986-12-31|

---

NO863432D0|1986-08-27|

---

DK413986A|1987-03-01|

---

CA1299507C|1992-04-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4500910A|1982-11-30|1985-02-19|Rca Corporation|Hue control system|

---

US4529595A|1983-01-13|1985-07-16|The Salk Institute For Biological Studies|GRF Analogs|

---

US4528190A|1983-10-25|1985-07-09|The Salk Institute For Biological Studies|GRF Analogs IV|

---

US4518586A|1983-01-13|1985-05-21|The Salk Institute For Biological Studies|GRF Analogs III|

---

IL70530A|1983-01-13|1986-09-30|Salk Inst For Biological Studi|Synthetic peptides having growth hormone releasing factor activity and compositions containing them|

---

US4595676A|1983-04-26|1986-06-17|The Salk Institute For Biological Studies|Rat hypothalamic GRF|

---

US4514331A|1983-06-29|1985-04-30|University Patents, Inc.|Peptide hormones with calcitonin-like activity|

---

US4649131A|1984-09-24|1987-03-10|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|US4734399A|1985-08-06|1988-03-29|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

US4828988A|1986-05-15|1989-05-09|Smith Kline - Rit|Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine|

---

US5565606A|1986-10-21|1996-10-15|Hoechst Aktiengesellschaft|Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method|

---

US4784987A|1987-01-13|1988-11-15|The Salk Institute For Biological Studies|GRF analogs VI|

---

IL84758A|1987-01-13|1992-03-29|Salk Inst For Biological Studi|Peptides stimulating the release of pituitary growth hormone in fish and amphibians,and pharmaceutical compositions containing them|

---

US4843064A|1987-01-13|1989-06-27|The Salk Institute For Biological Studies|GRF analogs V|

---

IL86102A|1987-05-11|1994-04-12|Univ Tulane|Alkylated growth hormone-releasing peptides and use thereof|

---

US5112808A|1987-05-11|1992-05-12|American Cyanamid Company|Alkylated hormone-releasing peptides and method of treatig mammals therewith|

---

US5098995A|1987-05-22|1992-03-24|The Salk Institute For Biological Studies|GRF Analogs VIIA|

---

US5002931A|1987-05-22|1991-03-26|The Salk Institute For Biological Studies|GRF analogs VII|

---

DE3742633A1|1987-12-16|1989-06-29|Hoechst Ag|PEPTIDES WITH INFLUENCING EFFECT ON HYPOPHYSIS IN MAMMALS|

---

US5043322A|1988-07-22|1991-08-27|The Salk Institute For Biological Studies|Cyclic GRF analogs|

---

US5756458A|1989-06-16|1998-05-26|Pharmacia & Upjohn Company|Stabilized potent GRF analogs|

---

WO1991016923A1|1990-05-04|1991-11-14|The Administrators Of The Tulane University Educational Fund|Novel synthetic grf analogs|

---

AU656144B2|1990-06-29|1995-01-27|F. Hoffmann-La Roche Ag|Histidine substituted growth hormone releasing factor analogs|

---

EP0565536A1|1990-11-14|1993-10-20|PHARMACIA & UPJOHN COMPANY|Stabilized, potent grf analogs|

---

DE69108192T2|1990-12-10|1995-07-20|Hoffmann La Roche|Process for the enzymatic production of GRFNH2.|

---

JPH05507939A|1991-04-09|1993-11-11|

---

JPH06507402A|1991-04-24|1994-08-25|

---

US5262519A|1991-05-15|1993-11-16|The Salk Institute For Biological Studies|GRF analogs XI|

---

US5550212A|1993-12-17|1996-08-27|The Administrators Of The Tulane Educational Fund|Analogues of hGH-RHNH2 having antagonistic activity|

---

JPH07200419A|1993-12-28|1995-08-04|Nec Corp|Bus interface device|

---

US5792747A|1995-01-24|1998-08-11|The Administrators Of The Tulane Educational Fund|Highly potent agonists of growth hormone releasing hormone|

---

EP0820296A4|1995-04-14|1999-06-30|Univ Tulane|Analogs of growth hormone-releasing factor|

---

US7268113B2|2001-02-02|2007-09-11|Conjuchem Biotechnologies Inc.|Long lasting growth hormone releasing factor derivatives|

---

US20060128615A1|2002-09-18|2006-06-15|Pierrette Gaudreau|Ghrh analogues|

---

US20090088380A1|2007-07-12|2009-04-02|Pierrette Gaudreau|Ghrh analogs and therapeutic uses thereof|

---

WO2009108364A2|2008-02-27|2009-09-03|Ipsen Pharma S.A.S.|Antagonistic analogues of ghrh|

---

WO2011153491A2|2010-06-03|2011-12-08|University Of Miami|Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets|

---

US9079974B2|2011-12-21|2015-07-14|The University Of Miami|GH-RH analogs with potent agonistic effects|

---

WO2014100816A2|2012-12-21|2014-06-26|University Of Miami|Ghrh agonists for islet cell transplantation and function and the treatment of diabetes|

---

EP2934565B1|2012-12-21|2019-03-13|University of Miami|Ghrh agonists for the treatment of ischemic disorders|

---

US9988428B2|2016-04-19|2018-06-05|Griffon Pharmaceuticals Inc.|Pegylated bioactive peptides and uses thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/770,683|US4689318A|1985-08-29|1985-08-29|GRF analogs|

---